Lightstone Ventures and ClavystBio led a $57.5m Series D round in Allay Therapeutics.

A private equity firms, Lightstone Ventures and ClavystBio led a $57.5m Series D round in Allay Therapeutics, a clinical-stage biotechnology company, with participation from Arboretum Ventures, Vertex Growth, Vertex Ventures Healthcare, and Brandon Capital. “Lightstone Ventures is pleased to be joined by a strong syndicate of biotechnology and medical device investors in the U.S. and Asia to support Allay with this fundraise to advance the Company’s platform of products into pivotal clinical development. The Company is enrolling its Phase 2b registration trial ATX101 in the US for TKA surgeries and are expecting early completion of this trial in the coming months. It is rewarding to see Allay, which Lightstone Singapore helped to incubate alongside our partners at the Foundry, continue to grow and prosper,” Mike Carusi, Lightstone Ventures Managing Partner.